Update on the role of antipsychotics in the treatment of Tourette syndrome

Huys, Daniel; Hardenacke, K.; Poppe, Pia; Bartsch, Christina; Baskin, Burak; Kuhn, Jens

doi:10.2147/ndt.s12990

Cited by 44 publications

(17 citation statements)

References 110 publications

(132 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Aripiprazole also has good evidence of effect in tic and Tourette's syndrome and is a partial dopamine agonist . Other neuroleptics, such as sulpiride, arisulpiride, and pimozide, are used to treat tic disorder in parts of the world, although the best evidence of effect exists for risperidone and aripiprazole in Tourette's syndrome. All neuroleptics, including aripiprazole, can cause extrapyramidal adverse effects .…”

Section: Symptomatic Therapiesmentioning

confidence: 99%

Current therapies and therapeutic decision making for childhood‐onset movement disorders

2019

View full text Add to dashboard Cite

Movement disorders differ in children to adults. First, neurodevelopmental movement disorders such as tics and stereotypies are more prevalent than parkinsonism, and second, there is a genomic revolution which is now explaining many early‐onset dystonic syndromes. We outline an approach to children with movement disorders starting with defining the movement phenomenology, determining the level of functional impairment due to abnormal movements, and screening for comorbid psychiatric conditions and cognitive impairments which often contribute more to disability than the movements themselves. The rapid improvement in our understanding of the etiology of movement disorders has resulted in an increasing focus on precision medicine, targeting treatable conditions and defining modifiable disease processes. We profile some of the key disease‐modifying therapies in metabolic, neurotransmitter, inflammatory, and autoimmune conditions and the increasing focus on gene or cellular therapies. When no disease‐modifying therapies are possible, symptomatic therapies are often all that is available. These classically target dopaminergic, cholinergic, alpha‐adrenergic, or GABAergic neurochemistry. Increasing interest in neuromodulation has highlighted that some clinical syndromes respond better to DBS, and further highlights the importance of “disease‐specific” therapies with a future focus on individualized therapies according to the genomic findings or disease pathways that are disrupted. We summarize some pragmatic applications of symptomatic therapies, neuromodulation techniques, and some rehabilitative interventions and provide a contemporary overview of treatment in childhood‐onset movement disorders. © 2019 International Parkinson and Movement Disorder Society

show abstract

Section: Symptomatic Therapiesmentioning

confidence: 99%

Current therapies and therapeutic decision making for childhood‐onset movement disorders

2019

View full text Add to dashboard Cite

show abstract

“…However, CBT represents a useful complement to the medication and current guidelines suggest that CBT should be offered as first-line treatment to suitable patients, where such intervention is available [80].…”

Section: ▪ Psychosocial Interventions For Ticsmentioning

confidence: 99%

Bridging neuroscience and clinical psychology: cognitive behavioral and psychophysiological models in the evaluation and treatment of Gilles de la Tourette syndrome

2013

View full text Add to dashboard Cite

SUMMARYCognitive neuroscience and clinical psychology have long been considered to be separate disciplines. However, the phenomenon of brain plasticity in the context of a psychological intervention highlights the mechanisms of brain compensation and requires linking both clinical cognition and cognitive psychophysiology. A quantifiable normalization of brain activity seems to be correlated with an improvement of the tic symptoms after cognitive behavioral therapy in patients with Gilles de la Tourette syndrome (GTS). This article presents broad outlines of the state of the current literature in the field of GTS. We present our clinical research model and methodology for the integration of cognitive neuroscience in the psychological evaluation and treatment of GTS to manage chronic tic symptoms.

show abstract

“…Although there is strong evidence in favor of pharmacological intervention, it is also known that medications can rarely eradicate tics completely and are always associated with unwanted side effects. The most commonly observed adverse events of typical antipsychotics are extrapyramidal reactions, neuroleptic malignant syndrome, drowsiness, restlessness, and sexual dysfunction; sulpiride may lead to sustained sedation or drowsiness [ 13 – 15 ].…”

Section: Introductionmentioning

confidence: 99%

The effectiveness and safety of plum-blossom needle therapy for Tourette syndrome: study protocol for a randomized controlled trial

et al. 2015

Trials

View full text Add to dashboard Cite

BackgroundPrevious studies have indicated that acupuncture can alleviate the symptoms of Tourette syndrome (TS), but the evidence is insufficient. So far, there have been no reports on plum-blossom needle therapy for TS. Here we present a protocol for a randomized controlled trial using plum-blossom needle therapy to treat TS.Methods/designSixty patients will be randomly allocated into either the plum-blossom needle therapy group or the habit reversal training (HRT) group. All patients in each group will be given 12 weeks of treatment, with follow-up at the 24th week. The primary outcome measure will be the mean change from baseline in the total tic score on the Yale Global Tic Severity Scale (YGTSS) at the 12th week. Secondary outcome measures will include the scores on the TS Clinical Global Impression Scale (CGI) and the mean changes from baseline in the YGTSS score and the Children and Adolescents’ Quality of Life Scale (CAQOL) at other time points. Safety will also be evaluated.DiscussionThis trial will evaluate the effectiveness and safety of plum-blossom needle therapy for TS compared with HRT. A limitation of this trial is that patients and acupuncturists cannot be blinded.Trial registrationClinicalTrials.gov Identifier: NCT02403258 (Date of registration: March 31, 2015).

show abstract

Update on the role of antipsychotics in the treatment of Tourette syndrome

Cited by 44 publications

References 110 publications

Current therapies and therapeutic decision making for childhood‐onset movement disorders

Current therapies and therapeutic decision making for childhood‐onset movement disorders

Bridging neuroscience and clinical psychology: cognitive behavioral and psychophysiological models in the evaluation and treatment of Gilles de la Tourette syndrome

The effectiveness and safety of plum-blossom needle therapy for Tourette syndrome: study protocol for a randomized controlled trial

Contact Info

Product

Resources

About